Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sangamo (SGMO) Partner Pfizer (PFE) is Encouraged by Emerging Data from SB-525 - Truist Securities
August 20, 2020 10:57 AM EDTTruist Securities analyst Nicole Germino reiterated a Buy rating and $22.00 price target on Sangamo BioSciences (NASDAQ: SGMO) after talking with management following BMRN's unexpected CRL. Management noted partner Pfizer (NYSE: PFE) is encouraged by emerging data from SB-525
The analyst... More
Baird Reiterates Outperform Rating on The TJX Companies (TJX) Following 2Q
August 20, 2020 7:08 AM EDTBaird analyst Mark R. Altschwager reiterated an Outperform rating and $65.00 price target on The TJX Companies (NYSE: TJX) following the company's 2Q earnings report. Sales in the quarter fell 32% with stores closed ~1/3 of the quarter and open-store-comp sales -3%. Management cited some logistical challenges disrupting... More
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL
August 19, 2020 11:30 AM EDTBaird analyst Michael Ulz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $140.00) while maintaining an Outperform rating after the company announced a CRL on Valrox.
The analyst commented, "Overall, we view the update as disappointing and assume at least a two-year delay in time-line."
... More